ENDRA Life Sciences Inc.
NDRA | NASDAQ
$6.31
+$0.81 (+14.73%)
At close: Sep 21, 2026, 4:00 PM ET
$6.33
+$0.02 (+0.32%)
Pre-market:
Sep 22, 2026, 9:23 AM ET
Company Profile
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
Key Executives
| Name | Position |
|---|---|
| Alexander Y. Tokman | Chief Executive Officer & Chairman |
| Richard Jacroux | Chief Financial Officer & Secretary |
| Idan Steinberg | Head of Engineering |
| Jonathan Behr | Co-Founder |
| Scott Sober | Head of Operations |
| Ziad Rouag | Head of Regulatory & Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 21, 2026 | 425 | Filing |
| Aug 20, 2026 | 425 | Filing |
| Aug 17, 2026 | 425 | Filing |
| Aug 17, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 425 | Filing |
| Aug 05, 2026 | 425 | Filing |
| Aug 04, 2026 | 425 | Filing |
| Jul 22, 2026 | 425 | Filing |
| Jul 22, 2026 | 425 | Filing |
ENDRA Life Sciences Inc.
| Country | United States |
| IPO Date | Jun 29, 2017 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Alexander Y. Tokman |
Contact Details
3600 Green Court Ann Arbor,
Michigan 48105-1570 United States
Stock Details
| Ticker Symbol | NDRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001681682 |
| CUSIP Number | 29273B500 |
| ISIN Number | US29273B5003 |
| SIC Code | 3845 |
Add to Watchlist
Select watchlists to add or remove NDRA